[Utility of chromosome banding with ALU I enzyme for identifying methylated areas in breast cancer].

Cancer is a group of disorders characterized by uncontrolled cell growth which is produced by two successive events: increased cell proliferation (tumor or neoplasia) and the invasive capacity of these cells (metastasis). DNA methylation is an epigenetic process which has been involved as an important pathogenic factor of cancer. DNA methylation participates in the regulation of gene expression, directly, by preventing the union of transcription factors, and indirectly, by promoting the "closed" structure of the chromatine.

Trisomy 19 and t(9;22) in a patient with acute basophilic leukemia.

We report a case of acute basophilic leukemia with two coexisting clonal abnormalities, t(9;22) and trisomy 19. The blast showed positive reaction with myeloperoxidase but negative reaction with chloroacetate esterase and acid phosphatase. Metachromatic features of the blast were observed with toluidine blue stain.

[G138A polymorphism of the RNASEL gene and its association with the development of prostate cancer. Preliminary study].

Prostate Cancer (CAP), is a complex disease with a multifactorial origin. It is characterized by heterogenous patterns of growth of neoplasic tissue, varying widely in its progression, age of beginning and therapy response. It is considered as the second most common cause of death by cancer in men and, it has been estimated, that one of five, suffers of CAP through the course of his life.

[Frequency and clinicopathological associations of K-ras mutations in Venezuelan patients with colo-rectal cancer].

Mutations in the K-ras oncogene are common in colo-rectal cancer, which affect the biological behaviour and may influence the susceptibility to therapy in these tumors. The objective of this work was to identify the types of K-ras mutations observed in referred patients with colo-rectal cancer and to relate them to their degree of histological differentiation and clinical stage. Histopathological and clinical data were obtained from medical records.

[Relationship of oncogene C-erbB-2 amplification in breast cancer with pathological parameters and disease free survival].

Background: Proto-oncogene c-erbB-2 is located in chromosome 17 region q21 and codifies a 185 Kd protein, with tyrosine kinase activity. The amplification of this gene is associated with relapse and lower survival in breast cancer. Overexpression of this gene can be detected by immunohistochemistry (IHC).